Matthew James Pianko, MD

Drs Costello and Pianko close their discussion by sharing advice for clinicians administering bispecifics to their patients with relapsed/refractory multiple myeloma.

Experts discuss key data on the outpatient management of teclistamab.

Matthew Pianko, MD, explains how patients with relapsed/refractory multiple myeloma are monitored for CRS and ICANS.

Caitlin Costello, MD, shares her thoughts on administering teclistamab to patients with relapsed/refractory multiple myeloma in an outpatient setting.

Key opinion leaders discuss how bispecifics are administered at their institutions.

Experts review how the treatment landscape for relapsed/refractory multiple myeloma shifted with the addition of bispecifics, and the currently approved bispecifics available.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Closing thoughts on unmet needs in the multiple myeloma space, particularly disparities in the care of patients with MM of racial and ethnic minorities.

Dr. Cook and Dr. Pianko share their perspectives on optimizing treatment strategies for individual patients in order to maximize response and mitigate adverse events.

Clinical pearls for community oncologists concerning the real-world application of existing treatments while considering feasibility, cost, and ease of care.

Conversation centered around patient frailty, Dr. Cook and Dr. Pianko emphasize the importance of accurately assessing frailty and adjusting treatment plans accordingly.

A summary of updates from the MAIA and SWOG S0777 studies, with a focus on efficacy and tolerability data.

Joselle Cook, M.B.B.S and Matthew James Pianko, MD discuss available treatment options and goals of therapy for patients with transplant-ineligible NDMM.

Closing out the program, Dr Ajay Nooka comments on the structural and biological disparities of care in multiple myeloma between Black and Caucasian patients, including age of presentation, delay of diagnosis and treatment, access to treatment options, and treatment response.

A look at some of the unmet needs in transplant-eligible multiple myeloma, particularly within the high-risk patient population.

Ajay Nooka, MD, and Matthew James Pianko, MD, discuss how they risk stratify patients with transplant-eligible multiple myeloma and the corresponding treatment approaches.

Dr Matthew James Pianko details how he determines treatment duration and discontinuation for transplant-eligible multiple myeloma.

Following the 2022 American Society of Clinical Oncology Annual Meeting, experts in multiple myeloma discuss real-world evidence as it relates to the present-day treatment of patients.

Drs Nooka and Pianko discuss how they measure a successful treatment response in patients with transplant-eligible multiple myeloma after induction therapy.

An oncologist muses on the potential of real-world data in evaluating the use of a quadruplet regimen for newly diagnosed transplant-eligible multiple myeloma.

Ajay Nooka, MD, explains how he selects treatment regimens for patients with newly diagnosed transplant-eligible multiple myeloma in his clinical practice.

An expert reviews data from the ongoing GMMG HD7 (German) trial investigating isatuximab in combination with bortezomib, lenalidomide and dexamethasone (Isa-VRd) versus VRd in the treatment of transplant-eligible newly diagnosed multiple myeloma.

Dr Ajay Nooka describes key data from the uniquely-designed MASTER trial investigating daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (Dara-KRd) versus KRd in transplant-eligible newly diagnosed multiple myeloma.

Matthew James Pianko, MD, provides an overview of the recently updated data from the GRIFFIN trial and the role of quadruplet versus triplet regimens in the treatment landscape of transplant-eligible newly diagnosed multiple myeloma.